Apimeds expands leadership team with dr. susan kramer to lead product development and brian peters to lead its ai² division

Matawan, n.j.--(business wire)--apimeds pharmaceuticals us, inc. (nyse american: apus) (“apimeds” or the “company”), a clinical-stage biopharmaceutical company developing apitox, an intradermally administered, bee venom-based therapeutic, today announced two key additions to its executive leadership team. susan kramer, drph, has been appointed senior vice president of development, and brian peters has joined as head of the company's proprietary ai²™ division. dr. kramer brings more than 30 year.
APUS Ratings Summary
APUS Quant Ranking